New hope for tough stomach cancers: trial tests aggressive Pre-Surgery combo
NCT ID NCT04656041
Summary
This study is testing if adding a newer drug (liposomal irinotecan) to a standard, strong pre-surgery treatment plan works better for people with advanced cancer where the stomach meets the esophagus. The goal is to shrink the tumor as much as possible before surgery, aiming for no cancer cells left in the removed tissue. About 40 adults with this specific cancer, who haven't had prior treatment for it, will participate to see if this combination is safe and effective.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beth-Israel Deaconess Medical Center
NOT_YET_RECRUITINGBoston, Massachusetts, 02215, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Massachusetts General Hospital
RECRUITINGBoston, Massachusetts, 02115, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Massachusetts General Hospital at Newton Wellesley Hospital
RECRUITINGNewton, Massachusetts, 02462, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.